Searched for
ORAL DIABETIC DRUGS
'Cheaper than a gym, but still not selling': Nithin Kamath on why Indians aren't embracing popular weight-loss drugs- Kiran Mazumdar-Shaw warns against long-term GLP-1 use, urges caution over weight-loss drugs, says 'for those who are not diabetic or clinically obese...'
- These large-, mid- and small-cap stocks can give more than 25% return in 1 year, according to analysts
- UK approves Novo weight-loss pill to edge open European marketBritain's medicine regulator has approved Novo Nordisk's weight-loss pill. This makes the UK the first European market for the oral treatme...12 Jun, 2026, 08.36 AM IST
- Good news for diabetes & BP patients: Govt cuts prices of these 30 medicines, relief may reach pharmacies soonThe National Pharmaceutical Pricing Authority (NPPA) has fixed retail prices for 30 essential drug formulations, including those for diabet...01 Jun, 2026, 04.49 PM IST
- Cipla is aiming for 40-50 global product filings in three years, says MD Achin GuptaCipla is charting its next growth phase with a strong focus on innovation, complex generics, and biosimilars. The company plans significant...29 May, 2026, 05.30 AM IST
- Innovation, biosimilars, complex generics to drive Cipla's growth: Achin Gupta, MD & Group CEOAs Cipla approaches its centenary, the company is redefining its strategy by prioritizing innovation to amplify revenues. With ambitions to...29 May, 2026, 12.57 AM IST
- For both the compulsive trader and careful investor: 25 stocks to watch if risk appetite returns; some with upside potential, some notIf the price of crude oil softens, Indian equities may again see a risk-on phase. Tariff concerns are no longer the central issue; the larg...24 May, 2026, 04.23 PM IST
- Long-term Investing: Ecosystem with an edge called India; 12 large- mid- and small-cap stocks with upside potential of up to 34%Tactical investing should not be confused with long-term investing. In a world where geopolitical risk, commodity shocks, and uncertainty a...23 May, 2026, 10.24 PM IST
- Stocks in news: ITC, Nykaa, Lenskart, Ola Electric, IndusInd BankMarkets saw a volatile session with Nifty trading below the 23,800-24,000 resistance zone, though select heavyweight buying limited downsid...21 May, 2026, 06.43 AM IST
- No cosmetic job with jabs, warns drug regulator CDSCOThe notice issued by the Central Drugs Standard Control Organisation (CDSCO) cites provisions of the Drugs and Cosmetics Act, 1940, and the...21 May, 2026, 06.00 AM IST
- Dr Reddy’s launches oral semaglutide in IndiaDr Reddys Laboratories has launched its oral semaglutide biosimilar for type 2 diabetes in India. The drug, Obeda, is available in three ta...20 May, 2026, 08.06 PM IST
- Dr Reddy's launches oral semaglutide biosimilar Obeda in IndiaDr. Reddy's Laboratories proudly presents Obeda, a groundbreaking oral semaglutide biosimilar for managing Type 2 diabetes in India. This i...20 May, 2026, 06.28 PM IST
- Semaglutide race: Torrent grabs 38% market shareOver a dozen Indian companies have launched generic versions of the GLP1 drug used for diabetes and weight management since the expiry of N...08 May, 2026, 08.54 AM IST
- US Stocks: Eli Lilly raises annual forecasts as GLP-1 drugs fuel growthEli Lilly raised its annual profit and revenue forecasts and posted better-than-expected first quarter on Thursday, on steady demand for it...30 Apr, 2026, 05.17 PM IST
- Obesity drug market to gain as Indians pop the pill and Chinese bring moreIndia's obesity treatment market is set for a major shift by year-end. A wave of oral GLP1 weight-loss pills, including those from China, w...22 Apr, 2026, 03.31 PM IST
- Dr Reddy's gets nod to roll out generic oral semaglutide drug"The formulation was clinically evaluated in a head-to-head comparative study conducted in India, which established the non-inferiority to ...16 Apr, 2026, 07.31 AM IST
- Ahead of its time, a GLP-1 drug almost made it out of IndiaFifteen years back, Zydus Lifesciences introduced ZYOG1, an oral GLP-1 agonist that sparked excitement for its implications in diabetes man...04 Mar, 2026, 12.10 AM IST
- Novo Nordisk launches anti-diabetes pill semaglutide in IndiaNovo Nordisk, the Danish drug maker on Thursday announced the launch of oral semaglutide in India for treatment of type 2 diabetes.20 Jan, 2022, 10.02 PM IST
- Five diabetes drugs in top-10 selling list; overtakes anti-infective, antibiotic medsInsulin brand Human Mixtard, oral formulation Glycomet GP, insulin Lantus, oral formulations Galvus Met and Janumet are now in the top-sell...21 Jul, 2016, 01.09 PM IST
Load More
